Título : Actualización en el tratamiento de la enfermedad de Chagas crónica. |
Autor : Mas Pérez, Ismael |
Tutor: Acosta Soto, Lucrecia  Navarro Beltrá, Miriam |
Editor : Universidad Miguel Hernández de Elche |
Departamento: Departamentos de la UMH::Agroquímica y Medio Ambiente |
Fecha de publicación: 2021-05-27 |
URI : http://hdl.handle.net/11000/25887 |
Resumen :
Introducción: La enfermedad de Chagas o Tripanosomiasis americana es una enfermedad tropical desatendida producida por un protozoo parásito del grupo Kinetoplástida, en concreto la especie Trypanosoma cruzi, y transmitida por diversas especies de chinches de la familia Triatomiinae. Clínicamente co... Ver más
Introduction: Chagas Disease or American trypanosomiasis it is a neglected vector-borne disease produced by a protozoan parasite of the Kynetoplastida group, in particular the specie Trypanosoma cruzi, and transmitted by a wide group of species of bedbugs from Triatomiinae family. Clinically it consists of a first acute phase succeeded by a chronic phase which could course asymptomatic or lead to cardiomyopathy or to megasyndromes. Because of pharmacologic treatments produce high toxicity and their efficacy it is disputable in chronic patients, the need of therapeutic updates it is suggested.
Objectives: to review updated scientific information about current therapeutics of Chagas Disease in its chronic phase and their future perspectives.
Methods: Systematic review of the articles saved from scientific databases: Medline, The Cochrane Library, Embase, Scopus and The Web of Science.
Results and discussion: Of 349 articles saved, after applying exclusion and inclusion criteria, 10 articles were selected in humans which evaluate safety and effectiveness of chronic chagas disease treatment. On first line Benznidazole is used, however, its rate of adverse reactions it is elevated and its efficacy its inconsistent to stop the progression of the disease. It has been compared its use with some drugs (Allopurinol, Posaconazole, Itraconazole and Ravuconazole) but they have rare or nule effectiveness versus placebo. Investigation about treatment of disease must be continued to give more options to patients.
Conclussion: treatment of Chagas Disease, especially in its chronic phase shows a lack of therapeutic alternatives which leads to giving up the treatment and everything that entails. As well as provide new drugs, it is important to invest on epidemiologic surveillance measures and primary, secondary, and tertiary prevention.
|
Palabras clave/Materias: tripanosomosis americana trypanosoma cruzi terapia farmacológica |
Área de conocimiento : CDU: Ciencias aplicadas |
Tipo de documento : info:eu-repo/semantics/bachelorThesis |
Derechos de acceso: info:eu-repo/semantics/openAccess |
Aparece en las colecciones: TFG - Farmacia
|